Gastric Cancer Diagnostics Market size was valued at US$ 3.5 Bn in 2024 and is projected to reach US$ 6.9 Bn by 2035, growing ...
Doctors and cancer researchers in the United States are increasingly alarmed by a steady rise in colorectal cancer among ...
MRK banks on Capvaxive, Winrevair and other new launches to counter Keytruda's looming 2028 LOE and record long-term growth.
Lagging behind the PD-1xVEGF leaders, Crescent has strengthened its hand by licensing Kelun’s integrin beta-6 ...
Detailed price information for Crescent Biopharma Inc (CBIO-Q) from The Globe and Mail including charting and trades.
4d
Arcus Biosciences, Inc. (RCUS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Arcus Biosciences, Inc. ( RCUS) Citi Annual Global Healthcare Conference 2025 December 3, 2025 10:30 AM EST Yigal Nochomovitz - Citigroup Inc. Exchange Research Yigal Nochomovitz - Citigroup Inc., ...
Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancersJazz to host ...
Second, for our mRNA cancer immunotherapies, we have recently provided 2 Phase II updates that support and inform our current ...
The Poco F8 Ultra has a 6.9-inch OLED display, which Poco calls HyperRGB - their 'full RGB subpixel structure' does appear to ...
My 39-year-old brother was just diagnosed with gastric cancer. The diagnosis was especially shocking because of his age. Is ...
Clinical Trials Arena on MSN
Kelun-Biotech’s ADC plus Keytruda touts first-line success in late-stage NSCLC
GlobalData analyst Biswajit Podder notes that Sac-TMT-Keytruda could influence the NSCLC treatment paradigm on a regional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback